Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yongming Qu

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
Journal of Diabetes Science and Technology|May 4, 2017
Dose Unit Establishment for a New Basal Insulin Using Joint Modeling of Insulin Dose and Glycemic ResponseYongming Qu, Junxiang Luo, Parag Garhyan, et al.
Diabetes Care|January 29, 2010
Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metforminRalph A DeFronzo, Curtis Triplitt, Yongming Qu, et al.
Diabetes Care|November 8, 2013
Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargineRichard M Bergenstal, Julio Rosenstock, Edward J Bastyr, et al.
Journal of Diabetes|August 18, 2015
Reduction in short-acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1 diabetesJulio Rosenstock, Thomas C Blevins, Richard M Bergenstal, et al.
Diabetes, Obesity & Metabolism|August 4, 2016
Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trialsJulio Rosenstock, Michel Marre, Yongming Qu, et al.
Menopause (New York, N.Y.)|February 23, 2007
The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safetyDale W Stovall, Wulf H Utian, Margery L S Gass, et al.
The American Journal of Medicine|April 20, 2010
Effects of exenatide combined with lifestyle modification in patients with type 2 diabetesCaroline M Apovian, Richard M Bergenstal, Robert M Cuddihy, et al.
Current Medical Research and Opinion|January 26, 2008
Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysisLeonard C Glass, Yongming Qu, Sheila Lenox, et al.
Journal of Bone and Mineral Metabolism|August 29, 2006
Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosisToshitaka Nakamura, Jian Li Liu, Hirotoshi Morii, et al.
Clinical Therapeutics|June 17, 2008
Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week studySherwyn L Schwartz, Robert E Ratner, Dennis D Kim, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Journal of Diabetes Science and Technology|May 4, 2017
Dose Unit Establishment for a New Basal Insulin Using Joint Modeling of Insulin Dose and Glycemic ResponseYongming Qu, Junxiang Luo, Parag Garhyan, et al.
Diabetes Care|January 29, 2010
Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metforminRalph A DeFronzo, Curtis Triplitt, Yongming Qu, et al.
Diabetes Care|November 8, 2013
Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargineRichard M Bergenstal, Julio Rosenstock, Edward J Bastyr, et al.
Journal of Diabetes|August 18, 2015
Reduction in short-acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1 diabetesJulio Rosenstock, Thomas C Blevins, Richard M Bergenstal, et al.
Diabetes, Obesity & Metabolism|August 4, 2016
Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trialsJulio Rosenstock, Michel Marre, Yongming Qu, et al.
Menopause (New York, N.Y.)|February 23, 2007
The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safetyDale W Stovall, Wulf H Utian, Margery L S Gass, et al.
The American Journal of Medicine|April 20, 2010
Effects of exenatide combined with lifestyle modification in patients with type 2 diabetesCaroline M Apovian, Richard M Bergenstal, Robert M Cuddihy, et al.
Current Medical Research and Opinion|January 26, 2008
Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysisLeonard C Glass, Yongming Qu, Sheila Lenox, et al.
Journal of Bone and Mineral Metabolism|August 29, 2006
Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosisToshitaka Nakamura, Jian Li Liu, Hirotoshi Morii, et al.
Clinical Therapeutics|June 17, 2008
Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week studySherwyn L Schwartz, Robert E Ratner, Dennis D Kim, et al.
Pageof 8